Mo-Re Intravascular Members With Low MRI Susceptibility

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing implantable medical devices face challenges in maintaining advantageous mechanical properties while reducing magnetic susceptibility, particularly when inserted into lumens with small diameters.

Innovation Solution

The use of molybdenum-rhenium (Mo-Re) alloy, optionally alloyed with Ta, Ir, Rh, or Ru, and further enhanced with Hf to reduce magnetic susceptibility, is employed to form the elongate members of intravascular devices, providing improved mechanical properties such as higher Young's modulus and ultimate tensile strength.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If cobalt-chromium (Co-Cr) alloy is used to form stents, then radial force and mechanical strength are improved, but magnetic susceptibility increases causing MRI artifacts and radiopacity decreases

Engineering Contradiction:
Improveradial forceVSAvoidmagnetic susceptibility
Core Design Contradiction:
StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent changes the material composition parameters by using platinum-tungsten alloy with tungsten content of 8-15%, specifically optimizing the ratio to achieve both high radial force and low magnetic susceptibility. This parameter optimization resolves the contradiction between mechanical strength and MRI compatibility.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite platinum-tungsten alloy material that combines the advantages of both metals: platinum provides low magnetic susceptibility and high radiopacity, while tungsten contributes high radial force and mechanical strength. This composite material approach simultaneously addresses both requirements.

Inventive Principle:
Principle #40Composite materials

2Object-affected harmful factors

If platinum-tungsten (Pt-W) alloy with 8% tungsten is used, then magnetic susceptibility is reduced and radiopacity is improved, but radial expansion force becomes insufficient

Engineering Contradiction:
Improvemagnetic susceptibilityVSAvoidradial expansion force
Core Design Contradiction:
Object-affected harmful factorsVSStrength

Solution Approach 1:

The patent increases the tungsten content from the conventional 8% to a range of 8-15%, with specific embodiments at 10%, 12%, and 15%. This parameter change enhances the radial expansion force while maintaining acceptable magnetic susceptibility and radiopacity properties.

Inventive Principle:
Principle #35Parameter changes

3Strength

If tungsten content in platinum alloy is increased to enhance mechanical strength, then handling and manufacturability are improved, but brittleness increases compromising performance

Engineering Contradiction:
Improvemechanical strengthVSAvoidbrittleness
Core Design Contradiction:
StrengthVSReliability

Solution Approach 1:

The patent identifies and applies an optimal parameter range for tungsten content (8-15%). Within this range, the alloy achieves enhanced mechanical strength and manufacturability while avoiding excessive brittleness. The specific embodiments at 10%, 12%, and 15% demonstrate the optimal balance point.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This alloy allows for the production of smaller, more robust intravascular devices with better shape retention and delivery capabilities through small catheters, minimizing material brittleness and MRI artifacts.

Implementation Method 1

The use of molybdenum-rhenium (Mo-Re) alloy, optionally alloyed with Ta, Ir, Rh, or Ru, and further enhanced with Hf to reduce magnetic susceptibility, is employed to form the elongate members of intravascular devices, providing improved mechanical properties such as higher Young's modulus and ultimate tensile strength

Methodology Applied
Scientific EffectAlloying:

Implementation Method 2

further enhanced with Hf to reduce magnetic susceptibility

Methodology Applied
Scientific EffectMagnetic susceptibility reduction:

Data Source

PatentEP4194020B1Implantable medical device
Publication Date: 2026.03.11 STRYKER CORP
  • EP4194020B1 patent drawingFigure 1A~1C
  • EP4194020B1 patent drawingFigure 2A~2B
  • EP4194020B1 patent drawingFigure 3A

AI summary

An implantable medical device (10, 100, 200, 400, 500), comprising an elongate member (20, 250) made from a material comprising an alloy containing rhenium in combination with zirconium and/or hafnium.